Details of the Drug Combination

General Information of Drug Combination (ID: DCM5KAR)

Drug Combination Name
G-CSF Oblimersen
Indication
Disease Entry Status REF
Acute leukaemia Investigative [1]
Component Drugs G-CSF   DMVFDYU Oblimersen   DM7KI4E
N.A. N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of G-CSF
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Investigative [2]
G-CSF Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Granulocyte colony-stimulating factor receptor (G-CSF-R) TTC70AJ CSF3R_HUMAN Stimulator [4]
------------------------------------------------------------------------------------
Indication(s) of Oblimersen
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [3]
Multiple myeloma 2A83 Phase 3 [3]
Oblimersen Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4934).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.